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http://dx
2956Objective: Surveillance for patients undergoing thoracic endovascular aortic repair (TEVAR) for blunt thoracic
aortic injury (BTAI) varies. Annual chest computed tomographic angiography (CTA) is often recommended but
concerns about the risks and costs have emerged. The aim of this study was to examine the optimal follow-up
frequency based on 11-year outcomes and surveillance experience.
Methods: Seventy-six patients with BTAI received TEVAR from May 2002 to July 2013. Demographics,
cardiovascular risk factors, Injury Severity Score (ISS), types, sizes, timing, and outcomes of stent grafts
were collected retrospectively.
Results: Mean age was 39.7 years (range, 17-85 years); 8 (11%) were women. Mean ISS was 46.2  18.5
(deceased, 61.0  19.2; surviving, 44.2  17.6; P ¼ .023). Technical success was achieved in 71 patients
(93.4%). All-cause mortality was 7 (9.2%), 1 (1.3%) of which was related to the procedure. Six were lost to
follow-up (8%). To examine the effect of surveillance frequency on outcomes, after excluding the 2 most recent
(<1 year) surviving patients, we arbitrarily divided the remaining 61 with stable repairs based on the timing of
their follow-up: 36 underwent timely follow-up (within 6 months of the scheduled annual visit; clinical
examination, CTA, magnetic resonance angiography, and echocardiography); 25 had delayed follow-up
(>6 months after scheduled annual visit). No significant differences were found for survival, graft-related
complications, need for reintervention, except for postoperative hypertension, which was higher in the first
group. All surviving patients had excellent outcomes, with no cerebrovascular accidents, paraplegia, or
paraparesis; the median follow-up for both groups was 3 years (interquartile range 2.0-3.5, 1.5-5.4 years).
Conclusions: Midterm outcomes of TEVAR for patients with stable repair after BTAI are excellent, both with
timely (1.0-1.5 years) and delayed (>1.5 years) follow-up intervals after a median surveillance period of 3 years.
A larger prospective randomized study could lead to a more relaxed, but equally safe surveillance schedule for
these patients, lowering risks and costs. (J Thorac Cardiovasc Surg 2014;148:2956-61)See related commentry on page 2962.In the previous report1 from our institution, we published
our short-term results comparing the early use of thoracic
endovascular aortic repair (TEVAR) for patients with blunt
thoracic aortic injury (BTAI) in the proximal descending
aorta with open repair. Now that TEVAR is arguably the
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centers are encouraging.2,3
The optimal method of repair is still unknown and the
postoperative surveillance for patients undergoing TEVAR
for BTAI is still under discussion. Open repair is more
invasive, but interval posteroanterior and lateral chest
radiographs may constitute adequate postoperative
surveillance. Conversely, although TEVAR is less invasive,
surveillance imaging, usually annually, requires signifi-
cantly greater expenditure on resources and exposes
patients to the toxicity of intravenous contrast agents and
the risks of radiation. BTAI is more common in relatively
young people, therefore these concerns are even stronger
in this subset of patients. This report seeks to demonstrate
the safety of less frequent imaging in patients with stable
repairs, based on our outcomes and postoperative surveil-
lance experience with 76 patients over an 11-year period.PATIENTS AND METHODS
We retrospectively reviewed the records of 76 consecutive patients who
were referred to our tertiary trauma center from May 2002 to July 2013
with BTAI, either isolated or with associated injuries in other systems,
and who received a thoracic aortic stent graft during treatment. To ourgery c December 2014
Abbreviations and Acronyms
BTAI ¼ blunt thoracic aortic injury
CT ¼ computed tomography
CTA ¼ computed tomographic angiography
CVA ¼ cerebrovascular accident
IQR ¼ interquartile range
ISS ¼ Injury Severity Score
LSA ¼ left subclavian artery
RCT ¼ randomized control trial
RFA ¼ right femoral artery
TEVAR ¼ thoracic endovascular aortic repair
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Dknowledge, this is the largest series of TEVARs for patients with BTAI
published from a single institution. The Scientific and Ethics Committee
of our hospital approved the study. Seventy-two patients (94.7%) had
been in a motor vehicle accident; 4 patients (5.3%) had fallen accidentally
or suicidally and their aortic injury was the result of sudden deceleration.
All patients had aortic injury confirmed initially by a chest computed
tomography (CT) scan at 7-mm slice thickness, followed by computed
tomographic angiography (CTA) at 1/0.8 mm and reconstruction in 3
planes (axial, coronal, and sagittal) in cases of a proximal landing zone
less than 0.8 cm, in order to accurately define the feasibility of TEVAR.
Medical management was applied until definitive endovascular repair.
The types of thoracic stent grafts used were the Talent (n¼ 13) and Valiant
(n ¼ 42) (Medtronic, Inc, Minneapolis, Minn), the Relay (n ¼ 20) (Bolton
Medical, Sunrise, Fla), and the E-Vita Thoracic (n¼ 1) (Jotec, Hechingen,
Germany). All patients were managed in the angiographic suite under local
anesthesia, unless the patients were sedated because of concomitant
injuries (mainly head injuries). Stent grafts were delivered through the
femoral artery, after a cut-down exposure, with a 22F to 25F delivery
system, and digital aortography was performed through the left brachial
artery for injury confirmation and stent guidance. The delivery system
was promoted over an extra stiff wire guide (Lunderquist; Cook Medical,
Inc, Bloomington, Ind), with its flexible tip previously placed just distally
to the aortic valve through a 5F angiographic catheter (IMPRESS
Vertebral, Merit Medical Systems, Inc, South Jordan, Utah). We used stent
graft oversizing of 10%-15% compared with the aortic diameter on the
preoperative CTA.We believe that oversizing is appropriate for the healthy
aortic wall of patients with BTAI, only when adjacent dissection is not
present. If dissection coexists in these patients (a relatively rare entity),
we avoid oversizing. Heparin (5000 IU intravenous bolus) was given
only in lengthy procedures, but was avoided in cases of excessive
bleeding from other anatomic sites or if fast deployment was achieved.
Also, 40 mL of normal saline was administered to the delivery system
before the stent graft insertion to minimize the porosity phenomenon
(possibility of a transgraft endoleak, type 4, immediately after
deployment). Local papaverine was applied on the arterial site of insertion
(ie, the femoral artery) in cases of hemodynamic instability to enable the
access. In some young patients, in whom femoroiliac access seemed
limited in caliber, we have always found that their arterial wall elasticity
allowed for safe insertion of the delivery system in a glove over a hand
manner. However, if insertion had not been deemed feasible or safe, an
appropriate iliac or aortic conduit graft could have been used. Digital
subtraction angiography was performed on completion to evaluate
correct placement of the device, patency, and absence of endoleaks. The
role of the surgeons in the procedure was to provide open exposure
(cut-down) of the femoral artery and facilitate the insertion of the delivery
system; all of the actual 76 implantations were done by the interventional
radiologists.The Journal of Thoracic and CarWe retrospectively analyzed the data on the patients’ demographics,
preoperative cardiovascular risk factors (hypertension, diabetes
mellitus, hyperlipidemia, and smoking), comorbidities and previous
cardiothoracic surgery procedures, mode and anatomic extent of aortic
injury, concomitant injuries and Injury Severity Score (ISS), time between
the accident and the procedure, the type and size of stent grafts used, the
potential left subclavian artery (LSA) orifice coverage, and any subsequent
need for revascularization. Perioperative and postoperative outcomes were
also reviewed as follows:
(1) Technical success rate and the need for conversion to an open
procedure, immediate type 1 endoleak and procedure-related
vascular injury, length of hospital stay, stroke, paraplegia, and
all-cause and stent graft–related mortality within the index hospital
admission.
(2) Mid- and long-term graft-related sequelae (chest tightness, persistent
hypertension and fever), the position, integrity and potential presence
of endoleaks on the follow-up imaging (ie, CTA) and the need for
reintervention.Statistical Analysis
Quantitative variables are expressed asmean values (standard deviation)
or as median values (interquartile range [IQR]). Qualitative variables are
expressed as absolute and relative frequencies. The c2 and Fisher exact
tests were used for comparison of proportions. The Student t test or
Mann-Whitney test was computed for comparison of the mean values.
Life table analyses were used to calculate cumulative survival (standard
errors) for specific time intervals. Kaplan-Meier survival estimates were
graphed over the follow-up period (Figure 1). The multiple Cox
proportional-hazard model was used in a stepwise method (P for removal
was set at .1 and P for entry was set at .05) to determine independent factors
associated with survival. The assumption of proportional hazards was
evaluated by testing for interaction with a continuous time variable. All
reported P values are 2-tailed. The statistical analyses were conducted
using SPSS version 18.0 (SPSS, Inc, Chicago, Ill).RESULTS
The mean age of the patient cohort was 39.7 years
(range, 17-85 years) and 8 of the 76 patients (11%) were
women (Table 1). One patient had recently (5months before)
undergone an open aortic valve replacement. Mean ISS
was 46.2  18.5; the ISS was significantly different
between deceased (61.0  19.2) and surviving patients
(44.2 17.6; P¼ .023). In all patients treated with TEVAR,
BTAI was associated with intimal flaps and/or thrombus,
intramural or periadventitial hematomas, and/or pseudoa-
neurysms in the vicinity of the isthmus (BTAI classification,
grades I-III).4 Eighteen patients (23.7%) underwent a
delayed TEVAR, more than 24 hours after injury, either
because of other concomitant life-threatening injuries
requiring immediate intervention (eg, emergency laparot-
omy or craniotomy) or delayed arrival at our center. These
patients were managed medically with antihypertensive
and counterpulsation medications until they received
definitive treatment with TEVAR. Primary technical success
was achieved in 71 patients (93.4%). Five patients (6.6%)
had a type 1 endoleak, recognized immediately, and 4 of
them required another stent graft (cuff); 1 patient, who was
a Jehovah witness, had a severe aortic injury associateddiovascular Surgery c Volume 148, Number 6 2957
FIGURE 1. Kaplan-Meier survival estimates.
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Dwith pseudoaneurysm and overt rupture, and developed
profound hemodynamic instability 14 hours postoperatively
and died in the angiographic suite due to exsanguination
without any possibility for additional stent grafting. None
of the patients had a conversion to open procedure. Our
strategy for the proximal landing zone was as follows:
2 cm if the distance from the LSA orifice was greater than
2.0 cm, partial coverage of the LSA orifice if the distance
from the LSA orifice was 1.5 to 2.0 cm, and full coverage
of the LSA orifice if the distancewas less than 1.5 cm. Eleven
patients had their LSA orifice covered by the stent graft, but
only 2 patients with clinical ischemia of the left arm
were revascularized with carotid-subclavian bypass grafting.
One of them had an aberrant left vertebral artery originating
from the aortic arch. Themedian length of staywas 15.5 days
(IQR, 8.5-32 days). Two patients had complications from the
stent graft insertion site, the right femoral artery (RFA); in
the first case, the artery was occluded, but the patient was
treated conservatively and had a successful recovery. The
second patient was readmitted with a pseudoaneurysm in
the RFA, which was successfully drained and primarily
repaired. All-cause mortality within the index hospital
admission was 9.2% (7 patients) and procedure-related
mortality was 1.3% (the patient with a type 1 endoleak
who died in the angiographic suite). None of the treated pa-
tients experienced any procedure-related cerebrovascular
accident (CVA) or paraplegia/paraparesis. Kaplan-Meier2958 The Journal of Thoracic and Cardiovascular Sursurvival estimates are presented in Figure 1. The cumulative
event-free rate at 1 month was 90.0% (standard error ¼
4.0%); at 6 months, 1, 5, and 10 years, it was equal to
88.0% (standard error ¼ 4.0%). Multipe Cox regression
analysis in a stepwise method showed that increased age
(hazard ratio ¼ 1.04; 95% confidence interval, 1.01-1.08)
and increased ISS (hazard ratio ¼ 1.06; 95% confidence
interval, 1.01-1.11) were independently associated with
greater hazard. Only 6 patients (8%) were lost to follow-
up, which differentiates this report from almost all others.
This study’s follow-up closing window was between March
2013 and September 2013.
During the same 11-year period (May 2002 to July 2013),
only 8 patients underwent open surgical repair with synthetic
graft interposition for BTAI in our institution; the last one
was performed in August 2004 (BTAI from a fall).
To examine the effect of follow-up timing on mid- and
long-term outcomes, we focused on adherence to postoper-
ative follow-up by eligible patients. First, we excluded the
7 deceased patients, the 6 patients lost to follow-up and
the 2 most recent (<1 year) surviving patients. We then
arbitrarily divided the remaining 61 patients, all of whom
had stable repairs, with an adequate proximal landing
zone and no bird-beak appearance, into 2 groups, based
on the timing of their follow-up. The first group consisted
of 36 patients with a generally timely follow-up (clinical
examination and CTA/MRA/echocardiography) withingery c December 2014
TABLE 1. Demographics and clinical characteristics of the entire
cohort of patients
Characteristic n (%)
Sex
Male 68 (89.5)
Female 8 (10.5)
Mean age, y (SD) 39.7 (17.1)
Mode of injury
MVA 72 (94.7)
Fall 4 (5.3)
ISS, mean (SD) 46.2 (18.5)
Delayed (>24 h) TEVAR
No 58 (76.3)
Yes 18 (23.7)
LSA orifice covered
No 65 (85.5)
Yes 11 (14.5)
Primary technical success
No 5 (6.6)
Yes 71 (93.4)
Conversion to open procedure
No 76 (100)
Yes 0 (0)
Endoleak type I (immediate)
No 71 (93.4)
Yes 5 (6.6)
CVA
No 76 (100)
Yes 0 (0)
Paraplegia
No 76 (100)
Yes 0 (0)
Vascular access complications
No 74 (97.4)
Yes 2 (2.6)
Median length of stay, d (IQR) 15.5 (8.5-32)
All-cause index mortality 7 (9.2)
Graft-related mortality 1 (1.3)
Median follow-up, mo (IQR) 38 (25-66)
SD, Standard deviation; MVA, motor vehicle accident; ISS, Injury Severity Score;
TEVAR, thoracic endovascular aortic repair; LSA, left subclavian artery; CVA,
cerebrovascular accident; IQR, interquartile range.
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D6 months of the scheduled yearly visit and the second
group consisted of 25 patients with nontimely, delayed
follow-up (>6 months after their scheduled yearly visit).
There were no significant differences between the
2 groups, except from persistent hypertension, which was
more prevalent in the timely follow-up group (Table 2).
All patients had excellent outcomes, with no major
stent graft–related adverse events, no CVAs or paraplegia/
paraparesis, or need for reintervention at a median
follow-up of 3 years for both groups (IQR, 2.0-3.5 years
and 1.5-5.4 years, respectively). One patient from the timely
follow-up group was found to have a bicuspid aortic valve
and a 5.5-cm ascending aorta aneurysm 15 months
postoperatively and he had his ascending aorta replaced.The Journal of Thoracic and CarOne patient in the delayed follow-up group died at 5 years
due to unrelated causes.
DISCUSSION
Twenty-two years after the first TEVAR implantation
by Dake and Miller5 at Stanford, in a patient with a
postoperative enlarging descending thoracic aortic false
aneurysm, dissemination of this biotechnological advent
has been extensive, as has progress in the construction
and deployment method of stent grafts, with a resulting
decrease in periprocedural morbidity and mortality.
The advent of the new hybrid operating rooms, with ample
use of adequate, contemporary radiology equipment,
working space and support, will further streamline major
endovascular procedures, making them both safer and
easier to perform.
Aneurysmal disease is the most frequent indication for
endovascular aortic repair in the abdominal aorta, but there
are multiple pathologies of the thoracic aorta that can be
treated with TEVAR, such as aneurysms, dissections, and
traumatic injuries (BTAI).
The surveillance focus and frequency of follow-up for
patients after TEVAR should be dependent on the type of
underlying pathology. In the setting of BTAIs, patients are
usually young or middle-aged without any preexisting
aortic diseases. Theoretically, once excluded, the traumatic
aortic pseudoaneurysm in these patients should thrombose
and the otherwise normal aorta should heal without any
physiologic predisposition to further degeneration. On the
other hand, young patients usually have a more tightly
angulated aortic arch, which if combined with excessive
oversizing on a healthy, stiff aortic wall, could predispose
to device infolding and collapse. Thus, the most important
focus of the follow-up protocol in this case should be the
position and integrity of the stent graft device, rather than
size changes, branch patency, entry/reentry of false
channels and endoleaks, as in the case of aneurysms and
dissections. However, the frequency of postoperative
surveillance in this subgroup of patients (TEVAR after
BTAI) is still under discussion and remains empirically
annual in many centers, given the lack of evidence from
prospective randomized control trials (RCTs).
Moreover, postoperative surveillance in this subcohort of
patients after TEVAR is a challenging task. Young, healthy
adults, with sometimes severe concomitant injuries, tend to
neglect the follow-up protocol of an endovascular
procedure, which was executed with minimal perioperative
disturbance, despite concerns about the long-term efficacy
of this novel treatment. We actually had to phone patients
in the delayed follow-up group several times to persuade
them to visit the hospital for their clinical and imaging
reexamination. An interesting finding of our retrospective
analysis was that, among the group of patients with a timely
surveillance schedule, a significantly higher percentage haddiovascular Surgery c Volume 148, Number 6 2959
TABLE 2. Demographics, clinical characteristics, and outcomes of
systematic and nonsystematic follow-up patients groups
Systematic follow-up,
n (%)
PNo (N ¼ 25) Yes (N ¼ 36)
Sex
Male 22 (88.0) 32 (88.9) 1.000k
Female 3 (12.0) 4 (11.1)
Mean age, y (SD) 40.4 (15.0) 37.4 (17.3) .483z
Mode of injury
MVA 25 (100.0) 33 (91.7) .262k
Fall 0 (0.0) 3 (8.3)
Cardiovascular risk factors
Smoking
No 14 (56.0) 23 (63.9) .535*
Yes 11 (44.0) 13 (36.1)
Hypertension
No 21 (84.0) 26 (72.2) .282k
Yes 4 (16.0) 10 (27.8)
Hyperlipidemia
No 23 (92.0) 29 (80.6) .286k
Yes 2 (8.0) 7 (19.4)
Diabetes mellitus
No 24 (96.0) 35 (97.2) 1.000k
Yes 1 (4.0) 1 (2.8)
ISS, mean (SD) 40.1 (17.2) 33.4 (15.9) .133z
Clinical characteristics
Stent grafts used
Talent (Medtronic) 4 5 >.05
Valiant (Medtronic) 14 25 >.05
Relay (Bolton Medical) 6 6 >.05
E-Vita Thoracic (Jotec) 1 0 >.05
Stent graft size (mean),
mm (SD)
33.9 (4.1) 3
133.2 (21.4)
32.6 (3.4) 3
128.2 (24.2)
>.05
Delayed (>24 h) TEVAR
No 19 (76.0) 25 (69.4) .574*
Yes 6 (24.0) 11 (30.6)
LSA orifice covered
No 24 (96.0) 29 (80.6) .125k
Yes 1 (4.0) 7 (19.4)
Primary technical success
No 3 (12.0) 1 (2.8) .296k
Yes 22 (88.0) 35 (97.2)
Conversion to open procedure
No 25 (100.0) 36 (100.0) —y
Yes 0 (0.0) 0 (0.0)
Endoleak type I (immediate)
No 22 (88.0) 35 (97.2) .296k
Yes 3 (12.0) 1 (2.8)
Postoperative cerebrovascular accident
No 25 (100.0) 36 (100.0) 1.000
Yes 0 (0.0) 0 (0.0)
Postoperative paraplegia/paraparesis
No 25 (100.0) 36 (100.0) 1.000
Yes 0 (0.0) 0 (0.0)
Vascular access complications
No 24 (96.0) 35 (97.2) 1.000k
(Continued)
TABLE 2. Continued
Systematic follow-up,
n (%)
PNo (N ¼ 25) Yes (N ¼ 36)
Yes 1 (4.0) 1 (2.8)
Median length of stay,
d (IQR)
11.5 (5-26) 17.5 (10-38.5) .106x
Graft-related complications
Fever
No 25 (100.0) 33 (91.7) .262k
Yes 0 (0.0) 3 (8.3)
Hypertension
No 23 (92.0) 18 (50.0) .001*
Yes 2 (8.0) 18 (50.0)
Chest tightness
No 22 (88.0) 32 (88.9) 1.000
Yes 3 (12.0) 4 (11.1)
Median follow-up,
y (IQR)
3 (1.5-5.4) 3 (2-3.5) 1.000
Mortality (>1.5 y)
No 24 (96.0) 36 (100.0) .410
Yes 1 (4.0) 0 (0.0)
SD, Standard deviation; MVA, motor vehicle accident; ISS, Injury Severity Score;
TEVAR, thoracic endovascular aortic repair; LSA, left subclavian artery; IQR,
interquartile range. *Pearson c2 test. yNot computed because of no distribution.
zStudent t test. xMann-Whitney test. kFisher exact test.
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symptomatic hypertension had potentially alerted these
patients to the significance of regular surveillance.
Although concerns have recently been raised about
effective patient selection and appropriate use of TEVAR
for different aortic pathologies and patient subsets,6
consensus exists, based on observational evidence rather
than prospective RCTs, that BTAI is one of the most
effective indications for its use, which also coincides with
our 11-year experience and postoperative surveillance of
these patients.
However, we realized that in patients with stable repair,
outcomes did not differ much between those with regular
and those with irregular follow-up schedules, which ulti-
mately prompted us to launch this retrospective study.
The extent of aortic injury and the mix of stent graft types
and sizes used in those 2 groups were comparable, as was
their last follow-up time period and their demographic
characteristics, the timing of the intervention, and their
preexisting cardiovascular risk factors and ISS. To our
knowledge, this is the first attempt to analyze data on
postoperative surveillance for patients with BTAI treated
with TEVAR.Limitations
Two important limitations of our study are the moderate
number of patients, which undermines the statistical power
of the results, and the fact that it is retrospective, whichgery c December 2014
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the lack of longer-term follow-up data in establishing the
safety and efficacy of TEVAR; our study cannot provide
them because the median follow-up for both groups was
3 years. Potential graft-related complications include
material failure (eg, stent fractures and fabric fatigue; the
nitinol in certain stent grafts on bench testing is expected
to last only about 10 years), recurrent endoleaks, pseudoa-
neurysm formation, and stent graft migration, collapse,
stenosis, or thrombosis. The only way to identify any such
issues early enough would be regular and systematic
surveillance. Our results can only offer some insight into
the first 1 to 3.5 years of postoperative follow-up (IQR of
the timely follow-up group, which is included in the IQR
of the nontimely group).
However, it is important to initiate a scientific discussion
regarding the optimal frequency of surveillance for these
patients for the following reasons.
First, CT scans are not as safe as we might think7 and
because they are still the preferred imaging modality for
the follow-up of patients with BTAI treated with TEVAR,
they represent a significant amount of radiation exposure,
especially for the young trauma population, which can
lead to severe complications, such as radiation burns,
ulceration, renal toxicity by intravenous contrast agents
and, most important, the development of malignancies. A
calculation of the actual radiation doses delivered by
commonly performed CT studies (including chest CT)
and quantification of the associated cancer risks using the
National Research Council’s models found that the risk
of cancer from a single CT scan could be as high as 1 in
80.8 If this risk is multiplied by several times from CT
surveillance in the lifetime of a young patient treated with
TEVAR after BTAI, the resulting cumulative risk may
become prohibitively high.
Second, the cost of this intensive yearly follow-up
schedule will soon become a major issue for the budget of
hospitals and health systems, because the number of young
trauma patients will continue to increase. Concerns about
the uncritical use and cost of high-tech medical imaging
have already emerged, placing imaging in the policy
spotlight and solidifying the general agreement that aThe Journal of Thoracic and Carsubstantial number of imaging examinations are unneces-
sary and do not positively contribute to patient care.9
In conclusion, midterm outcomes of TEVAR for patients
with stable repair after BTAI are excellent, both with timely
(1.0-1.5 years) and delayed (>1.5 years) follow-up intervals
at a median surveillance of 3 years. However, we need
large, multicenter, randomized studies to establish a more
realistic, less intensive, but equally safe surveillance
schedule for carefully selected patients with stable repairs,
which would help to substantially reduce the associated
risks and costs.
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